Actively Recruiting
Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease
Led by Mayo Clinic · Updated on 2026-01-26
10
Participants Needed
1
Research Sites
107 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This early phase I trial tests the safety, side effects and how well medication combinations of dasatinib, quercetin, fisetin and temozolomide work in treating patients with glioma for which the patient has received treatment in the past (previously treated) and for tumor cells that remain after attempts to treat the tumor have been made (residual disease). Dasatinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply, which may help keep tumor cells from growing. Quercetin and fisetin are compounds found in plants. They have antioxidant and anti-inflammatory properties and help remove senescent cells, older or damaged cells that have stopped dividing but don't die off as they should and build up in tissues over time. Senescent cells may cause inflammation or damage to nearby healthy cells. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill tumor cells and slow down or stop tumor growth. Giving medication combinations of dasatinib, quercetin, fisetin and temozolomide may be safe, tolerable and/or effective in treating patients with previously treated glioma with residual disease.
CONDITIONS
Official Title
Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Prior diagnosis of glioma treated with chemotherapy and/or radiation with stable disease based on Response Assessment in Neuro-Oncology (RANO) criteria
- Must have IDH-mutant OR MGMT-methylated glioma
- Any radiographic evidence of residual disease is eligible
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- Karnofsky performance status of 50 or higher
- Hemoglobin 9.0 g/dL or higher within 15 days prior to registration
- Absolute neutrophil count (ANC) 1500/mm3 or higher within 15 days prior to registration
- Platelet count 100,000/mm3 or higher without transfusion within 7 days preceding lab assessment and within 15 days prior to registration
- Alanine aminotransferase (ALT) and aspartate transaminase (AST) levels 2.5 times upper limit of normal or less (or 5 times ULN for patients with liver involvement) within 15 days prior to registration
- Calculated creatinine clearance 45 ml/min or higher within 15 days prior to registration
- Average corrected QT interval (QTc) 450 ms or less on triplicate 12 lead electrocardiogram within 29 days prior to registration
- Negative serum pregnancy test for persons of childbearing potential within 8 days prior to registration
- Presence of an implanted cranial CSF access device such as Ommaya reservoir or ventriculoperitoneal shunt
- Willingness to provide blood and CSF samples for research
- Co-enrollment on the neuro-oncology biorepository for collection of blood and CSF samples
- Provide written informed consent
- Willingness to return to Mayo Clinic for follow-up
You will not qualify if you...
- Pregnant persons
- Nursing persons
- Persons of childbearing potential and persons able to father a child who are unwilling to use adequate contraception
- Patients unsuitable for the study due to current or past medical history or uncontrolled illness limiting safety or compliance
- Participants unable to swallow tablets or at risk for impaired oral medication absorption, including those with refractory vomiting or gastrointestinal resections
- Patients with known hypersensitivity or allergy to all of the study drugs
- Inability to undergo MRI scans
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Actively Recruiting
Research Team
C
Clinical Trials Referral Office
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here